This 1996 study published in the Journal of Clinical Investigation explores the molecular bridge between the immune system and the endocrine stress response. Researchers demonstrate that Leukemia Inhibitory Factor (LIF)—a cytokine typically associated with immune signaling—is a potent regulator of the pituitary gland, acting through the STAT signaling pathway to drive the production of the stress hormone precursor, proopiomelanocortin (POMC).
Abstract
Leukemia inhibitory factor (LIF) and the related cytokine oncostatin M (OSM) were found to induce basal and corticotropin-releasing hormone (CRH)-induced POMC mRNA and ACTH secretion in AtT20 cells. LIF action is receptor-mediated, involving the activation of STAT1 and STAT3 signaling pathways. Notably, LIF potently synergizes with both CRH and cAMP induction of POMC transcription, suggesting a novel intrapituitary signaling mechanism that mediates the neuroimmune-pituitary interface.
The Problem: Mapping the Neuro-Immune Interface
The hypothalamic-pituitary-adrenal (HPA) axis is the body's central command for stress. Traditionally viewed as a top-down system, the hypothalamus releases CRH, which triggers the pituitary to produce ACTH from its precursor, POMC. However, the presence of cytokines in the pituitary suggested an additional layer of regulation. This study sought to understand how immune signals like LIF influence hormone production at the molecular level and whether they act independently or in concert with standard stress signals.
Methods and Experimental Design
The researchers utilized AtT20 cells, a murine cell line mimicking pituitary corticotrophs. Their methodology included:
- Hormone Assays: Radioimmunoassays (RIA) to measure ACTH secretion and intracellular cAMP levels.
- Signal Transduction: Immunoprecipitation and Western blotting to track the phosphorylation of STAT1 and STAT3 proteins.
- Gene Regulation: Transfection with a luciferase reporter gene fused to the rat POMC promoter to identify specific DNA regions necessary for the LIF response.
- Immunoneutralization: Using antibodies to block the LIF receptor and the gp130 subunit to confirm receptor-mediated effects.
Key Results: Synergy and Secretion
The most striking finding was the massive synergy between LIF and CRH. While both molecules independently stimulate ACTH secretion, their combined effect is significantly greater than the sum of their individual parts.
As shown in Figure 1, 1 nM of LIF caused a roughly 4-fold induction of ACTH secretion, while CRH alone caused a 6-fold induction. However, the combination of the two reached a 20-fold increase, illustrating how an immune challenge can hyper-sensitize the pituitary to brain-derived stress signals.
Parallel Signaling Pathways
Interestingly, the study revealed that LIF and CRH use different intracellular "languages." While CRH acts primarily through the cAMP pathway, LIF does not significantly increase cAMP levels. Instead, LIF activates the JAK-STAT pathway, inducing rapid phosphorylation of STAT1 and STAT3.
This lack of convergence at the secondary messenger level (cAMP) suggests that the synergy occurs directly at the gene level, where LIF-activated STAT proteins and CRH-activated factors meet on the POMC promoter to amplify transcription.
Insights and Implications
- Autocrine Regulation: Immunoneutralization experiments suggested that corticotrophs use LIF in an autocrine fashion to maintain basal hormone levels.
- Glucocorticoid Feedback: Dexamethasone effectively blocked the LIF-induced response, confirming that the body's standard "off-switch" for stress remains functional even during cytokine-driven stimulation.
- The STAT Connection: The identification of the STAT pathway as the driver for LIF action provides a clear molecular mechanism for cytokine-mediated endocrine regulation.
Limitations
While AtT20 cells are a standard model, they are tumor-derived, and dynamics may differ in primary human pituitary cells. Additionally, the study identified a 115-kD protein co-immunoprecipitating with STAT1 whose exact role remains unknown. Future work is needed to definitively map the STAT binding sites on the POMC promoter.
Reference: Ray, D. W., Ren, S. G., & Melmed, S. (1996). Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J. Clin. Invest., 97(8), 1852–1859.
Summary updated